Health Care • Biotechnology: Commercial Physical & Biological Resarch
$5.23 ▼ -0.05
(-0.95%)
MKT CAP: $760.4M • VOL: 1.68M
52W L $1 52W H $5
OABI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $18.7M | $26.4M | $34.2M |
| YoY Revenue Growth % | -29.3% | -22.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$69.0M | -$74.5M | -$69.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$64.8M | -$62.0M | -$50.6M |
| EBITDA (Normalized) | -$68.5M | -$73.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$36.5M | -$39.7M | $2.3M |
| Capital Expenditures (CapEx) | $565.0K | $1.9M | — |
| Free Cash Flow (FCF) | -$37.0M | -$41.5M | $2.3M |
| FCF Margin % | -80.0% | -80.0% | 6.9% |
| Return on Invested Capital (ROIC %) | -22.6% | -22.6% | — |
| Cash & Short-Term Equivalents | $25.5M | $27.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $267.0M | $287.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OABI.